• Sulfo-NHS-SS-Biotin: Mechanism and Evidence

  2026-10-14

  The APExBIO product description identifies Sulfo-NHS-SS-Biotin, also called sulfosuccinimidyl-20(biotinamido)ethyl-1,3-dithiopropionate, as a water-soluble, primary-amine-reactive biotinylation reagent with a disulfide-cleavable spacer. Its documented scope includes protein and antibody labeling, affinity capture, detection, and conceptual cell-surface applications, but no identity-matched research study or comparative performance data were supplied.

• Neddylation, RIPK3 Degradation, and Viral Inflammation

  2026-10-14

  A primary Immunity study links an orthopoxvirus protein to SCF-dependent RIPK3 degradation, necroptosis suppression, and altered inflammation. MLN4924 HCl salt provides a conceptual pharmacological entry point for studying NEDD8-activating enzyme and cullin-RING ligase biology, but the supplied study does not establish that this compound was used or that NAE inhibition reproduces viral protein loss.

• Erastin and Ferroptosis: Evidence and Boundaries

  2026-10-13

  Erastin is a research tool for studying ferroptosis and oxidative cell death, but the supplied renal-injury study supports a context-specific mechanistic interpretation rather than broad claims about cancer selectivity, clinical treatment, or supplier-specific performance.

• What iTBS Findings in SCA3 Mice Show

  2026-10-12

  A recent mouse study reports that intermittent theta-burst stimulation improved motor coordination and altered cerebellar markers linked to ataxin-3 aggregation, neuroinflammation, and autophagy. The findings are mechanistically suggestive but remain preliminary: the work was conducted in a transgenic mouse model, used a small sample, and did not establish long-term disease modification or relevance to people with SCA3.

• Erastin, Ferroptosis, and ROS: Evidence Boundaries

  2026-10-12

  Erastin is commonly described as a ferroptosis inducer, but the supplied evidence does not connect it directly to the reported carrier-platin study. Liu et al. describe a distinct, preclinical platinum-based approach to rapid ROS-associated cancer-cell death, while important questions remain about mechanism, selectivity, reproducibility, and clinical relevance.

• Erastin Beyond the Benchmark: Ferroptosis to Translation

  2026-10-11

  Erastin is more than a ferroptosis inducer: it is a mechanistic lens for studying redox vulnerability, tumor heterogeneity, and the immune consequences of oxidative cell death. This analysis connects preclinical evidence with translational questions without overstating clinical readiness.

• Erastin and Ferroptosis: Evidence, Scope, and Limits

  2026-10-10

  A source-grounded overview of Erastin as a ferroptosis inducer, explaining ferroptosis principles, the strength of available evidence, interpretation of HCC findings, and the boundaries of conclusions from cell and database studies.

• Bafilomycin C1 in Lysosomal and Cardiac Research

  2026-10-09

  Bafilomycin C1 is commonly described as a vacuolar H+-ATPases inhibitor for studying lysosomal acidification, autophagy, and intracellular trafficking. This overview separates supplier information from peer-reviewed evidence and examines how lysosomal perturbation could be interpreted in high-content cardiotoxicity research without treating indirect findings as proof of compound-specific effects.

• RNA Pol II Inhibition and Active Cell Death Signaling

  2026-10-09

  Harper et al. show that RNA polymerase II inhibition can trigger apoptosis through active signaling rather than passive loss of transcription-dependent gene products. The study identifies loss of hypophosphorylated RNA Pol IIA and defines a Pol II degradation-dependent apoptotic response, providing a framework for interpreting transcription-targeting therapies in cancer research.

• From Surface Labeling to Spatial Proteome Maps

  2026-10-08

  Spatial proteomics is moving beyond isolated markers toward cell-type-resolved molecular maps of intact tissue. This thought-leadership article examines how membrane-restricted tyramide chemistry can support that transition, what the 2025 PSPro study demonstrates, and where Biotin-XX Tyramide Reagent fits—without confusing conceptual relevance with direct validation.

• DDIT4 Links Microplastics to Kidney Organoid Injury

  2026-10-08

  A 2025 study used human pluripotent stem cell-derived kidney organoids to examine how 1 μm polystyrene microplastics affect nephron development. The findings connect organoid injury with DDIT4-associated mTOR suppression, autophagy, and apoptosis, while also highlighting the limits of translating an organoid model into environmental or clinical risk estimates.

• Sodium Picosulfate and the Gut–Brain Axis

  2026-10-07

  A translational perspective on Sodium Picosulfate as a defined gastrointestinal perturbation for studying motility, electrolyte handling, microbiota, and neuroinflammation—while distinguishing supplier evidence from findings reported in a rat hepatic encephalopathy imaging study.

• CFDA SE Cell Tracer Kit Overview

  2026-10-07

  The CFDA SE Cell Tracer Kit (SKU K1023) is an APExBIO product containing carboxyfluorescein diacetate succinimidyl ester for supplier-described fluorescent cell labeling and conceptual applications in cell lineage tracing and cell proliferation studies. No matched paper evidence or independent performance data were provided.

• LmPLK1 in Locust Gut Growth and Molting

  2026-10-06

  The reference study characterizes LmPLK1 as a regulator connecting cell-cycle activity in the locust midgut with tissue maintenance, molting, and 20-hydroxyecdysone signaling. Its RNA-interference findings support LmPLK1 as a biologically important pest-control target, although the evidence remains species-specific and requires further validation beyond the reported study system.

• Direct Mouse Genotyping Kit Plus: From Genotype to Evidence

  2026-10-06

  The Direct Mouse Genotyping Kit Plus can simplify genotype confirmation in mouse disease models through direct lysate PCR and a PCR master mix with dye reagents. This article examines its scientific role in protecting model validity, using recent SCA3/MJD neuromodulation research to distinguish genotyping evidence from mechanistic conclusions.

8076 records 1/539 page Next 12345 下5页 Last page